CA3154317A1 - Antibiotic combination therapies - Google Patents

Antibiotic combination therapies Download PDF

Info

Publication number
CA3154317A1
CA3154317A1 CA3154317A CA3154317A CA3154317A1 CA 3154317 A1 CA3154317 A1 CA 3154317A1 CA 3154317 A CA3154317 A CA 3154317A CA 3154317 A CA3154317 A CA 3154317A CA 3154317 A1 CA3154317 A1 CA 3154317A1
Authority
CA
Canada
Prior art keywords
rifabutin
colistin
baumannii
antibiotic
antibiotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3154317A
Other languages
English (en)
French (fr)
Inventor
Vincent Trebosc
Christian Kemmer
Glenn E. Dale
Sergio Lociuro
Marc Gitzinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioversys AG
Original Assignee
Bioversys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioversys AG filed Critical Bioversys AG
Publication of CA3154317A1 publication Critical patent/CA3154317A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3154317A 2019-09-12 2020-08-03 Antibiotic combination therapies Pending CA3154317A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US62/899,257 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US62/902,019 2019-09-18
US201962941160P 2019-11-27 2019-11-27
US62/941,160 2019-11-27
US202062977659P 2020-02-17 2020-02-17
US62/977,659 2020-02-17
PCT/IB2020/000645 WO2021048610A1 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies

Publications (1)

Publication Number Publication Date
CA3154317A1 true CA3154317A1 (en) 2021-03-18

Family

ID=72432957

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3154317A Pending CA3154317A1 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies
CA3154129A Pending CA3154129A1 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3154129A Pending CA3154129A1 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions

Country Status (17)

Country Link
US (6) US11207305B2 (https=)
EP (3) EP4028001B1 (https=)
JP (4) JP7769605B2 (https=)
KR (1) KR20220103698A (https=)
CN (3) CN115052597B (https=)
AU (2) AU2020344214B2 (https=)
BR (2) BR112022004672A2 (https=)
CA (2) CA3154317A1 (https=)
ES (1) ES2982067T3 (https=)
HR (1) HRP20240818T1 (https=)
HU (1) HUE066936T2 (https=)
MX (1) MX2022003077A (https=)
PH (1) PH12022550610A1 (https=)
PL (1) PL4028001T3 (https=)
RS (1) RS65681B1 (https=)
SM (1) SMT202400250T1 (https=)
WO (2) WO2021048610A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) * 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645508B1 (en) * 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN101362067A (zh) * 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
PT2247291T (pt) * 2008-02-08 2019-02-01 Red Hill Biopharma Ltd Métodos e composições para tratamento de doença inflamatória do intestino
MY158809A (en) 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
US10064858B2 (en) * 2011-01-31 2018-09-04 The United States Of America, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
CN102178604B (zh) 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
RU2472512C1 (ru) * 2011-12-06 2013-01-20 Общество С Ограниченной Ответственностью "Ибмх-Экобиофарм" Противотуберкулезная композиция и способ ее получения
WO2016013986A1 (en) * 2014-07-25 2016-01-28 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
CN107148479A (zh) * 2014-09-04 2017-09-08 赛拉诺斯股份有限公司 病原体和抗微生物剂抗性检测
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
EP3291798A4 (en) * 2015-05-04 2019-01-16 Gufic Biosciences Limited FREEZE-DRIED PHARMACEUTICAL FORMULATION OF RIFABUTIN AND METHOD FOR THE PRODUCTION THEREOF
JP7072898B2 (ja) * 2016-08-16 2022-05-23 ユニバーシティ オブ ロチェスター ポリミキシンｂ／トリメトプリム系の治療薬を含有する医薬組成物
JP2020506236A (ja) 2017-02-07 2020-02-27 エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ 長期間持続するオートファジー誘発のための同位体増強アンブロキソール
US11701346B2 (en) * 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii

Also Published As

Publication number Publication date
HRP20240818T1 (hr) 2024-10-11
EP4028001B1 (en) 2024-04-10
WO2021048610A1 (en) 2021-03-18
AU2020347536A1 (en) 2022-04-14
JP2026016690A (ja) 2026-02-03
KR20220103698A (ko) 2022-07-22
US20250281469A1 (en) 2025-09-11
PL4028001T3 (pl) 2024-07-22
CN115052597B (zh) 2025-07-08
AU2020344214A1 (en) 2022-04-21
US11833139B2 (en) 2023-12-05
CN120860031A (zh) 2025-10-31
JP2022548252A (ja) 2022-11-17
US20220184048A1 (en) 2022-06-16
BR112022004672A2 (pt) 2022-06-07
EP4028001C0 (en) 2024-04-10
US11351158B2 (en) 2022-06-07
CN114980889A (zh) 2022-08-30
ES2982067T3 (es) 2024-10-14
WO2021048611A1 (en) 2021-03-18
JP2025176113A (ja) 2025-12-03
BR112022004645A2 (pt) 2022-06-21
EP4028000A1 (en) 2022-07-20
SMT202400250T1 (it) 2024-07-09
AU2020347536B2 (en) 2025-09-25
JP7804570B2 (ja) 2026-01-22
MX2022003077A (es) 2022-07-11
JP7769605B2 (ja) 2025-11-13
US11207305B2 (en) 2021-12-28
RS65681B1 (sr) 2024-07-31
US20230132691A1 (en) 2023-05-04
US11766425B2 (en) 2023-09-26
US12257241B2 (en) 2025-03-25
CN115052597A (zh) 2022-09-13
US20210077472A1 (en) 2021-03-18
EP4420673A2 (en) 2024-08-28
CA3154129A1 (en) 2021-03-18
US20210077471A1 (en) 2021-03-18
JP2022551228A (ja) 2022-12-08
EP4420673A3 (en) 2024-11-06
AU2020344214B2 (en) 2026-01-22
HUE066936T2 (hu) 2024-09-28
PH12022550610A1 (en) 2023-03-13
US20240041845A1 (en) 2024-02-08
EP4028001A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
Hagel et al. Perioperative antibiotic prophylaxis and antimicrobial therapy of intra-abdominal infections
US12370184B2 (en) Antibiotic combination therapies
JP5782615B2 (ja) オリタバンシンの単回用量を用いる治療の方法
JP2025176113A (ja) 抗生物質併用療法
Metallidis et al. Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty
Insler et al. Successful treatment of methicillin-resistant Staphylococcus aureus keratitis with topical ciprofloxacin
EP2714034B1 (en) Compositions comprising cefepime and tazobactam
JP2022539583A (ja) マイコプラズマ・ジェニタリウムによって引き起こされる感染症の治療のための組合せ
Gothi et al. Resistant TB: newer drugs and community approach
US20230364065A1 (en) Antibiotic combination therapies
KR20110095856A (ko) 아즈트레오남과 카르바페넴류인 메로페넴 및 에르타페넴의 상승작용적 조합
Inoshita et al. A randomized prospective study of oral levofloxacin vs intravenous flomoxef prophylaxis in postoperative infection after endoscopic sinus surgery
Nord Use of newer quinolones for the treatment of intraabdominal infections: Focus on clinafloxacin
US20190388437A1 (en) Compositions and methods for treating bone and joint infections
Ohnishi et al. Treatment of Japanese patients with enteric fever using azithromycin and MIC levels for causative organisms
Vanderloo et al. Minocycline Hydrochloride: The Emerging Evidence of Its Therapeutic Value in Complicated Bacterial Infections.
EA007713B1 (ru) Ассоциации дальфопристин/хинупристин с цефпиромом
Pawar et al. Newer antibiotics for musculoskeletal infections
Furlanut et al. Guidelines on Antibiotic Combination in ICU Patients

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240730

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240730

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240730

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241104

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250410

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250610

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250610

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250717

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251113

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260114

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260115